公开(公告)号：US12049505B2

公开(公告)日：2024-07-30

申请号：US16705124

申请日：2019-12-05

申请人： CytomX Therapeutics, Inc.

发明人： Olga Vasiljeva ,  Michael B. Winter

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C12N15/11 ,  C12N15/62 ,  C12N15/63

CPC分类号： C07K16/2863 ,  A61P35/00 ,  C07K7/06 ,  C12N15/11 ,  C12N15/62 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/50

摘要： The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP) in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20230192798A1

公开(公告)日：2023-06-22

申请号：US17938536

申请日：2022-10-06

申请人： CytomX Therapeutics, Inc.

发明人： Alexey Yevgenyevich Berezhnoy ,  Nicole G. Lapuyade ,  Na Cai ,  Michael B. Winter ,  Kenneth Wong ,  Madan M. Paidhungat ,  Dylan L. Daniel ,  Erwan Le Scolan

IPC分类号： C07K14/56 ,  C07K16/28 ,  A61P35/00

CPC分类号： C07K14/56 ,  C07K16/2896 ,  A61P35/00

摘要： Provided herein are methods of treating a subject by administering a combination of an activatable cytokine construct (ACC) and a PD-1/PD-L1 pathway inhibitor in which the ACC includes: a first monomer construct including an optional first peptide mask (PM1), an optional third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and a second monomer construct including an optional second peptide mask (PM2), an optional forth cleavable moiety (CM4), a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), wherein the CM2 is positioned between the CP2 and the DD2; wherein the DD1 and the DD2 bind to each other thereby forming a dimer of the first monomer construct and the second monomer construct; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.